EIKN
Eikon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$10.96
+0.00%Income statement
| Metric | 2025 |
|---|---|
| Revenue | |
| Total Revenue | — |
| Cost of Revenue | 24.2M |
| Gross Profit | (24.2M) |
| Operating Expenses | |
| R&D Expense | 250.3M |
| SG&A Expense | 88.6M |
| General & Admin Expense | 88.6M |
| Selling & Marketing Expense | — |
| Other Expenses | (24.2M) |
| Total Operating Expenses | 314.8M |
| Cost and Expenses | 338.9M |
| Operating Income (EBIT) | (338.9M) |
| Non-Operating | |
| Interest Income | 15.6M |
| Interest Expense | 837.0K |
| Net Interest Income | 14.7M |
| Other Non-Op Income/Expense | 14.7M |
| Non-Operating Income (excl Interest) | (15.5M) |
| EBT (Pre-Tax Income) | (324.2M) |
| Income Tax Expense | — |
| Bottom Line | |
| Net Income | (324.2M) |
| Earnings from Cont. Ops | (324.2M) |
| Earnings from Discont. Ops | — |
| Bottom Line Net Income | (333.6M) |
| Per Share | |
| Basic EPS | ($6.16) |
| Diluted EPS | ($6.16) |
| Revenue Per Share | $0.00 |
| Shares | |
| Basic Shares Outstanding | 54.1M |
| Diluted Shares Outstanding | 54.1M |
| Profitability Metrics | |
| EBITDA | (299.2M) |
| D&A | 24.2M |
| EBIT | (323.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026